 HomeNewsAbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis

AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis

2021-11-19

AbbVie today announced new results from a post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial evaluating RINVOQ® (upadacitinib; 15 mg, once daily) in patients with moderate to severe rheumatoid arthritis (RA) on stable background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with prior inadequate response or intolerance to at least one biologic DMARD.

Results showed that 34% of patients receiving RINVOQ and background csDMARDs achieved Clinical Disease Activity Index (CDAI) remission (CDAI ≤2.8) at first occurrence of response before week 60, while 79% achieved CDAI low disease activity (LDA) (CDAI ≤10).1 Maintenance of response, defined as not losing response at two consecutive study visits, was seen for CDAI remission and CDAI LDA in 39% and 61% of patients, respectively, at 60 weeks.1 The study results (Abstract #1694) are among the 38 abstracts across multiple rheumatic diseases being presented by AbbVie at the American College of Rheumatology (ACR) Convergence 2021, taking place virtually Nov. 3-9.

"Many people living with rheumatoid arthritis continue to experience debilitating joint pain and decreased physical functioning despite being on therapy," said Thomas Hudson, M.D., senior vice president, research and development, chief scientific officer, AbbVie. "These data underscore the potential of RINVOQ to be an important treatment option to help people who face the daily challenges of rheumatoid arthritis."

Of patients treated with RINVOQ who lost CDAI remission, 58% remained in CDAI LDA, and 22% recaptured remission by the analysis cut-off date.1 Similar patterns of sustained response were observed for remission and LDA based on Simplified Disease Activity Index (SDAI) criteria and for DAS28(CRP) ˂2.6/≤3.2.1

"Achieving remission or low disease activity are the primary treatment goals for people with rheumatoid arthritis. I'm encouraged by these data, which add to the growing body of evidence that upadacitinib may help more people living with rheumatoid arthritis take control of this chronic, progressive disease and reach these important treatment goals," said Professor Ronald van Vollenhoven, M.D., Ph.D., chair of rheumatology and director, Amsterdam Rheumatology Center (ARC).

Previous: Eli Lilly's oral JAK inhibitor Olumiant (Baritinib): 9.3 years of treatment, with long-term good safety!

Next: Jardiance®(empagliflozin) shows continuous heart and kidney benefits: regardless of the state of kidney disease!

 HomeNewsAbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis

Shandong Haohong Biotechnology Co., Ltd.